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Abstract 
Importance: Schizophrenia is a highly heritable, polygenic condition characterized by a relatively 
diverse phenotype, and frequent comorbid conditions such as anxiety and depression. There is 
currently limited evidence on how high genetic risk for schizophrenia is manifest in the general 
population. 
Objective: To investigate the extent to which genetic risk for schizophrenia is associated with 
different phenotypes during adolescence in a population-based birth cohort.  
Design: Cohort study using the Avon Longitudinal Study of Parents and Children (ALSPAC) 
Setting: General population 
Participants: Adolescents (N 3676 to 5447 depending on outcome investigated) 
Exposure: Polygenic risk scores (PRSs) for schizophrenia generated for individuals in ALSPAC using 
results of the second Psychiatric Genomics Consortium Schizophrenia genome-wide association 
study as a training set. 
Main outcomes and measures: Logistic regression was used to assess associations between 
schizophrenia PRS and a) psychotic experiences (using PLIKSi at 12 and 18 years), b) negative 
symptoms (CAPE at 16.5 years), c) depressive disorder (DAWBA at 15.5 years) and d) anxiety 
disorder (DAWBA at 15.5 years) in adolescence.  
Results: PRSs created using single nucleotide polymorphisms with a training set p value ≤ 0.05 were 
associated with negative symptoms (OR per SD increase in PRS = 1.21, 95% CI = 1.09, 1.36; R2 = 
0.007) and anxiety disorder (OR per SD increase in PRS = 1.17, 95% CI = 1.06, 1.29; R2 = 0.005). No 
evidence was found of an association between schizophrenia PRS and psychotic experiences (OR per 
SD increase in PRS = 1.08, 95% CI = 0.98, 1.19; R2 = 0.001) or depressive disorder (OR per SD increase 
in PRS = 1.02, 95% CI = 0.91, 1.13; R2 = 0.00005). Results were mostly consistent across different 
training set p value thresholds and using different cut-offs and measures of the psychopathologies.  
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Conclusions: We demonstrate polygenic overlaps between common genetic polymorphisms 
associated with schizophrenia and both negative symptoms and anxiety disorder, but not with 
psychotic experiences or depression. As schizophrenia genetic risk is more commonly manifest as 
anxiety and negative symptoms during adolescence a greater focus on these phenotypes rather than 
on psychotic experiences might be required for prediction of transition in at-risk samples. 
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Background 
Schizophrenia has a heritability of approximately 80% and genome-wide association studies (GWAS) 
provide strong evidence of multiple independent loci contributing to the aetiology of this disorder.1  
The importance of studying the phenotypic manifestations of increased genetic liability for 
schizophrenia has long been recognised and originally involved small samples of individuals at high 
risk as indexed by having a family history.2 Genetic advances now provide the opportunity to extend 
the power and generalizability of high-risk studies into the general population by examining 
individuals according to genetic risk. Whilst individual loci have small effects on risk, multi-locus 
approaches show that cumulatively, alleles on current GWAS platforms explain half to a third of the 
genetic risk for schizophrenia.3,4 Furthermore, information from even moderately associated alleles 
can be collapsed into a single polygenic risk score (PRS) that can be used to explore shared genetic 
effects with other disorders and examine how genetic risk is manifest early during development in 
the general population.5 
Schizophrenia is defined by the presence of psychotic experiences (hallucinations, delusions and 
thought disorder) and negative symptoms such as blunted affect and apathy, although cognitive 
deficits are also common as is comorbidity with other diagnoses, particularly affective and anxiety 
disorders.6 Longitudinal studies show that anxiety, depression, and cognitive deficits often predate 
schizophrenia7-11 indicating that these phenotypes might represent early expression of schizophrenia 
genetic risk. Whilst some degree of genetic overlap across psychiatric disorders is commonly 
found,12-15 knowledge of how genetic risk is most commonly expressed at different stages of the life 
course could help understanding of aetiological mechanisms, identify individuals at highest-risk for 
developing schizophrenia, and inform targeted interventions. 
Three previous studies have used a schizophrenia PRS generated from a GWAS training set capturing 
≈3% of the proportion of risk variance4 to examine associations with symptoms that characterise 
schizophrenia. In the first study, schizophrenia PRS was not associated with symptom dimensions 
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characteristic of the disorder in either schizophrenia cases or controls.16 Similarly, there was no 
association with positive symptom, cognitive and negative symptom dimensions in a general 
population sample of adolescents,17 whilst we observed no strong evidence that schizophrenia PRS 
was associated with psychotic experiences at age 12 within a population-based birth cohort, the 
Avon Longitudinal Study of Parents and Children (ALSPAC).18 Since then however, a larger GWAS has 
been completed which explains a substantially greater proportion of risk variance,1 and thus 
provides greater power19 to examine how genetic risk is manifest during development. 
The aim of this study is to examine the psychopathology associated with early expression of genetic 
risk for schizophrenia, and more specifically, whether a schizophrenia PRS derived from the most 
recent GWAS is associated with i) psychotic experiences, ii) negative symptoms, iii) anxiety disorders, 
or iv) depression during adolescence in a large, population-based sample. 
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Methods 
Participants 
The sample comprised of young individuals within the ALSPAC cohort. The initial cohort consisted of 
14,062 children born to women residing in the former Avon Health Authority area with an expected 
delivery date between April 1991 and December 1992 (www.alspac.bris.ac.uk, see 
http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary for all available data).20,21 All 
subjects provided written informed consent and ethical approval for the study was obtained from 
the ALSPAC Law and Ethics Committee and the Local Research Ethics Committees. 
 
Genetic Data 
Genetic data were acquired from 9912 participants using the Illumina HumanHap550 quad genome-
wide single nucleotide polymorphism (SNP) genotyping platform. Following quality control 
assessment, imputation and restricting to 1 young person per family, genetic data were available for 
8230 individuals (see eMethods for more detail). 
 
Measures 
Psychotic experiences 
The semi-structured Psychosis-Like Symptom Interview (PLIKSi)22,23 was used to assess psychotic 
experiences (such as hallucinations, delusions or experiences of thought interference) at ages 12 and 
18 years. To maximise the numbers within our sample, individuals were deemed as having a 
psychotic experience if rated as having one or more definite psychotic experiences at either age 12 
or 18 years, compared to no or only suspected psychotic experiences at age 12 or 18 years. See 
eMethods for more detail on the PLIKSi, and on the other outcome measures used in this study. 
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Negative Symptoms 
These were assessed using 10 questions based on items from the Community Assessment of Psychic 
Experiences (CAPE) self-report questionnaire24 at age 16.5 years (see eMethods and eTable 1) which 
measures negative symptoms such as apathy, anergia and asociality. Each item was rated on a 4-
point scale (0: never, 1: sometimes, 2: often, 3: always). A total score was constructed based on the 
sum of responses (minimum score: 0, maximum score: 30). A binary variable was created using a 
total score of 14 as a cut-off, chosen to approximately define the top decile (9.18%) of the sample. 
Depressive Disorder and Anxiety Disorder  
Depression and anxiety disorder outcomes were derived from the semi-structured Development and 
Well Being Assessment (DAWBA) interview at age 15.5 years, a valid instrument in community and 
clinical samples.25 DSM-IV and ICD-10 diagnoses of depressive or any anxiety disorder were 
generated using a computerised diagnostic algorithm that predicts the likelihood of a clinical 
diagnostic rating (see http://www.DAWBA.com for more information).26 
We defined individuals as having a depressive disorder or an anxiety disorder if they were 
categorised in the DAWBA band predicting a ≥ 15% probability of clinical diagnosis, a cut-off selected 
to approximately define the top deciles of the sample. 
 
We conducted a series of sensitivity analyses using different phenotype-score cut-offs to define 
binary outcomes, and using different measures where available to test the robustness of our 
findings (see eMethods). 
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Polygenic Risk Score 
Construction of PRSs follows the methodology described by the International Schizophrenia 
Consortium (ISC).4 PRSs were constructed using results from the second Psychiatric Genomics 
Consortium (PGC) Schizophrenia GWAS (eMethods).1 
Polygenic scores were calculated for each ALSPAC individual using the PLINK (v1.07)27 ‘score’ 
command. Scores which sums the number of risk alleles present for each SNP (0, 1 or 2) weighted by 
the logarithm of its odds ratio (OR) for schizophrenia from the PGC.  
Our primary analysis used scores generated using a list of SNPs with a GWAS training set p value 
threshold (pT) ≤ 0.05, the threshold that maximally captures schizophrenia liability.1 As the 
composition of a PRS is a balance between true and null effects,28 scores generated using lists of 
SNPs meeting a series of p value thresholds and using all independent SNPs meeting genome-wide 
significance as reported by the PGC Schizophrenia GWAS 1 were used as sensitivity analyses. 
 
Statistical analysis 
Logistic regression was used to test association between outcomes and schizophrenia PRS. Results 
are presented as ORs and 95% confidence intervals (CIs) per standard deviation (SD) increase in PRS. 
Nonlinear associations between PRSs and outcomes were examined by inclusion of quadratic terms. 
We examined whether associations with our outcomes were independent by inclusion of all 
phenotypes within a multivariable model.  To correct for multiple testing arising from using different 
pT within our sensitivity analyses, permutation-adjusted p values were computed (eMethods). 
To test whether the effect size of schizophrenia PRS was the same, or different, across phenotypes, 
we used bivariate probit regression to jointly model pairs of outcomes. We tested equality of 
regression parameters expressing the effect of schizophrenia PRS (pT of 0.05) on each outcome using 
a likelihood ratio test to compare a model that allows effect estimates to differ with a model where 
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the PRS effect was constrained to be equal for both outcomes 29,30. All statistical analyses were 
performed using Stata (Version 13; StataCorp LP, College Station, TX, USA). 
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Results 
Associations between schizophrenia polygenic score and psychopathology 
The numbers of individuals who participated in the PLIKSi at age 12 and 18 years or completed 
questions relating to negative symptoms at age 16.5 years and depression and anxiety at age 15.5 
years are shown in Table 1.  
There was no strong evidence that individuals who had a higher PRS, and thus increased genetic risk 
for schizophrenia, had an increased risk of developing psychotic experiences (OR per SD increase in 
PRS = 1.08, 95% CI = 0.98, 1.19; permutation‐adjusted p = 0.142; Nagelkerke R2 = 0.001) (Figure 1a & 
eTable 2).  
We observed strong evidence of association between schizophrenia PRS and negative symptom 
score at age 16.5 (OR = 1.21, 95% CI = 1.08, 1.36; permutation‐adjusted p = 0.001; R2 = 0.007) (Figure 
1b & eTable 2). There was also strong evidence that individuals with a higher schizophrenia PRS were 
at an increased risk of anxiety disorder at age 15.5 years (OR per SD increase in polygenic score = 
1.17, 95% CI 1.06, 1.29; permutation‐adjusted p = 0.0017; R2 = 0.005) (Figure 1d & eTable 2). There 
was no strong evidence of association between PRS and depressive disorder at age 15.5 years (OR 
per SD increase in polygenic score = 1.02, 95% CI 0.91, 1.13; permutation‐adjusted p = 0.770; R2 = 
0.00005) (Figure 1c & eTable 2).  
There was no strong evidence to support non-linear effects of polygenic risk on any of the 
phenotypes examined. Results per decile of PRS for training set p-threshold of 0.05 are presented in 
eTable 3. Associations with negative symptoms and anxiety disorder were independent, persisting 
when testing all phenotypes within a multivariable model (eTables 4-7). 
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Common and specific associations with schizophrenia polygenic score  
Tetrachoric correlations between each psychopathology are shown in eTable 8. The results of the 
bivariate analyses, examining whether schizophrenia PRS (pT = 0.05) effect sizes are similar or 
different across phenotypes, are summarised in Table 2. We observed some evidence that the 
strong associations between schizophrenia PRS and both negative symptoms and anxiety are 
different to that of PRS on depression (p=0.020 & p=0.020 respectively), with weaker evidence that 
they are different from effects of PRS on psychotic experiences (p=0.141 & p=0.105). There was no 
strong evidence that the association between PRS effect and negative symptoms differed from that 
on anxiety (p=0.917). 
 
Sensitivity analyses 
Our results were unchanged when using different cut-off values or different measurement tools to 
assess our outcomes (see eFigures 1-5), when adjusting for parental self-reported history of 
schizophrenia or depression or when excluding individuals with a psychotic disorder at age 18. 
Results were also consistent across all training set p-thresholds for all outcomes with exception of 
psychotic experiences where there was weak evidence that increased genetic risk was associated 
with a decreased risk of psychotic experiences at lower training set p-thresholds (pT ≤ 1x10-7; OR per 
SD increase in polygenic score = 0.90, 95% CI 0.81, 0.99; permutation‐adjusted p = 0.037, R2 = 0.002) 
(Figure 1a & eTable 2). 
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Discussion 
In this study we examined how increased genetic risk for schizophrenia is manifest phenotypically 
during adolescence in the general population. We found no strong evidence of association with 
occurrence of psychotic experiences or depressive disorder. However, there was strong evidence 
that negative symptoms and anxiety disorders were more common in adolescents with higher 
genetic risk, and that these were independent of each other. 
Whilst it may seem surprising that schizophrenia genetic risk is not associated with psychotic 
experiences in adolescence, these findings are consistent with previous studies that have examined 
this relationship.17,18 The estimates of association and strength of evidence in this study are very 
similar to those from a previous study using ALSPAC even though power here is substantially greater 
given the use of a much larger training set to generate the risk-scoring algorithm.  
At p-thresholds that maximally capture schizophrenia liability, psychotic experiences were more 
common in those with higher genetic risk, albeit the confidence intervals included the null. At the 
most stringent p-thresholds however, there was weak evidence that genetic risk was associated with 
reduced psychotic experiences. This could be due to random error, or could result from attrition 
bias. Missing data is likely greater for those who develop a psychotic disorder and for those at high 
genetic risk. It is possible therefore that psychotic experiences are under-represented in high 
compared to low genetic risk participants included in these analyses, akin to the apparently 
protective effect of smoking on Alzheimer’s disease seen using risk rather than rate models of 
analysis.31 It is not clear though why this would only be observed at p-thresholds that explain less of 
the variance for schizophrenia. 
There are a number of potential explanations for our findings of strong evidence of association 
between schizophrenia genetic risk and negative symptoms and anxiety disorder, but not with 
psychotic experiences in the general population. First, it is possible that genetic risk for 
schizophrenia is expressed heterotypically during adolescence as anxiety and negative symptoms, 
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and that psychotic experiences develop later during development. For the minority of individuals 
who go on to develop schizophrenia, anxiety and negative symptoms would represent prodromal 
symptoms of the disorder. This implies that hallucinations and paranoid beliefs arising during 
adolescence might be explained to a greater degree by non-genetic effects such as childhood 
trauma32,33 or cannabis use34 than by genetic risk for schizophrenia in comparison to psychotic 
experiences arising later in life.  The association between schizophrenia genetic risk and psychotic 
experiences might therefore get stronger with increasing age akin to that seen for general cognitive 
ability.35  
It is highly plausible that anxiety and negative symptoms occur as early manifestations of genetic risk 
for schizophrenia, and we might speculate on possible mechanisms. For example, disturbed 
biological processes secondary to genetic variation might result in subtle alterations in prediction 
error processing and attributional salience that might lead to anxiety prior to onset of clear-cut 
psychotic phenomena.36,37 Whilst this might arise from processes primarily affecting mesolimbic 
pathways, prefrontal cortical abnormalities might lead to subtle cognitive deficits and impairment of 
motivational drive and emotion that are observed as negative symptoms. Schizophrenia genetic risk 
is also associated with impaired childhood performance IQ in this cohort (under review), though it is 
not known whether variants acting primarily through different brain pathways are differentially 
related to these phenotypes. 
Second, it is possible that genetic risk for schizophrenia is expressed during adolescence as increased 
psychotic experiences as well as anxiety and negative symptoms, but that psychotic experiences are 
observed with greater measurement error; thus associations would be relatively underpowered for 
this phenotype. Use of a semi-structured interview and similar estimates using questionnaires 
suggests this is an unlikely explanation, but cannot be excluded. 
Third, it is possible that genetic variants identified as showing association with schizophrenia in the 
GWA studies only weakly index risk for hallucinations and delusions, and more strongly reflect risk 
for other characteristics of the disorder such as negative symptoms that index severity or chronicity 
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of illness, and which might be selected for in clinically-ascertained samples. Similarly, such 
ascertainment might be biased towards those with multiple morbidities, for example co-morbid 
anxiety disorders. Studies that have examined symptom dimensions within schizophrenia38 and in 
the general population39,40 show that heritability of negative and disorganised symptoms is greater 
than that of positive symptoms, and that schizophrenia polygenic risk is more strongly associated 
with negative and disorganised symptoms than positive symptoms.41  
Whilst evidence exists of genetic overlap between schizophrenia and major depressive disorder in 
adults12,42 we found no evidence to support this in our study. It is possible that measures of 
depression in this study capture more transient disorders in adolescence that obscures a genetic 
overlap between schizophrenia and a more persistent, chronic form of depression. 
Our results indicate that anxiety and negative symptoms are likely to be the best markers of high 
schizophrenia genetic risk in population-based samples, however we note that the variance of these 
phenotypes explained by schizophrenia genetic risk is small (0.5%-0.7%) and that the negative 
symptoms measure used in the general population might not fully capture negative symptoms seen 
in schizophrenia. Our findings have potentially important implications for studies of at-risk samples 
where current approaches for informing prediction of transition rely heavily on psychotic 
experiences. Our results are consistent with an evolving literature describing anxiety as a common 
symptom during the prodromal stage of psychosis.43-45  
Our study has a number of strengths. First, we used the most recent schizophrenia GWAS from the 
PGC,1 the largest schizophrenia dataset available as a training set, thus minimising measurement 
error. Second, we used a large, well characterised, relatively homogenous population-based sample 
for examining psychosis-related phenotypes during adolescence, a key period of development that 
closely predates the start of the peak in incidence of schizophrenia. Third, we used a semi-structured 
interview to determine the presence of psychotic experiences, as is used clinically. We also used 
multiple measures of depression and anxiety at different ages during adolescence, and different cut-
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offs of these and measures of psychotic experiences and negative symptoms as sensitivity analyses 
to test the robustness of our findings.  
There are also a number of limitations of our study. First, despite the use of one of the largest 
population-based birth cohorts worldwide with the required data, our sample may not be 
adequately powered to identify small-sized effects of cumulative genetic risk on the phenotypes 
examined,19 especially given potential differences in heritability across the phenotypes.14,39,40 Given 
that our sample is too small to estimate heritability of the phenotypes accurately, it is at present 
difficult to determine whether the absence of significant polygenic association between a phenotype 
and genetic risk for schizophrenia reflects an absence of genetic correlation, or inadequate power. 
Second, missing data in the cohort could potentially lead to bias in our estimates. Whilst it is possible 
that selective missingness has led to over-estimates of association it seems unlikely that this has 
occurred for some of our phenotypes but not others. A further limitation is that rare genetic variants 
are not captured by GWAS, and therefore we are only able to examine the effect of common 
variants (as captured by current GWA studies) on adolescent phenotype expression.  
Our results highlight the need for GWAS consortia of schizophrenia to include detailed phenotyping 
data to examine to what extent current GWA findings relate to specific phenotypes, and to identify 
genetic variants and pathways that are symptom domain specific rather than examining presence of 
disorder per se. Furthermore, large population-based longitudinal studies with robust measures of 
these phenotypic constructs are required to determine how schizophrenia genetic risk is expressed 
from childhood through adulthood to study if this changes with age, to examine potential mediators 
and moderators of risk, and determine usefulness of genetic risk scores for prediction of transition 
to psychosis. A better understanding of how genetic risk for schizophrenia manifests during 
development could inform early recognition of problems in those at greatest risk, and potentially 
inform targeted interventions. 
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Figure legends 
Figure 1. Associations between A) psychotic experiences, B) negative symptoms, C) depressive 
disorder and D) anxiety disorder and polygenic scores for schizophrenia generated using lists of 
SNPs meeting a series of p value thresholds (PT). Odds ratio per standard deviation (SD) change in 
polygenic risk score are shown with upper and lower 95% confidence intervals. Grey bars: log10 
number of SNPs used to create polygenic risk scores. Genome-wide significant (5e-08) PT = polygenic 
score created from 111 genome wide significant schizophrenia SNPs as reported by PGC.1 
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Tables 
 
Table 1. Number of individuals (all and those genotyped only) with outcome measure (psychotic 
experiences, negative symptoms, depression and anxiety) 
Age 
(years) 
Data 
source 
Outcome 
measure 
Outcome 
measure type 
N 
participants  
N (%) with 
outcome 
N 
genotype
d 
N (%) with 
outcome 
12 
PLIKSi 
Psychotic 
Experiences 
Binary 
(yes/no) 
6,792 383 (5.64) 5,103 280 (5.49) 
18 4,718 229 (4.85) 3,486 168 (4.82) 
12 & 18† 7,452 575 (7.72) 5,444 419 (7.70) 
16.5 CAPE 
Negative 
Symptoms 
Binary (score 
</≥ 14) 
5,095 467 (9.17) 3,673 337 (9.18) 
15.5 DAWBA Depression 
Binary (</≥ 
15% band) 
5,365 498 (9.28) 4,106 373 (9.08) 
15.5 DAWBA Anxiety 
Binary (</≥ 
15% band) 
5,367 
596 
(11.10) 
4,107 444 (10.81) 
† Individuals who completed at least 1 interview session at age 12 and/or 18 
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Table 2. Effects of schizophrenia polygenic risk score (per SD; discovery sample p-threshold = 0.05) on 
psychopathologya, and examination of whether psychopathology-specific effects differ from a 
common effect 
   Phenotype specific effect Common effect 
   Phenotype 1 Phenotype 2  
Phenotype 1 Phenotype 2 n OR (LCI,UCI) OR (LCI,UCI) OR (LCI,UCI) Pb 
Psychotic 
experiences 
Negative 
symptoms 
3288 
1.037  
(0.934, 1.150) 
1.146  
(1.039, 1.263) 
1.094 
(1.015, 1.179) 
0.141 
Depressive 
disorder 
3965 
1.059  
(0.966, 1.161) 
1.024  
(0.939, 1.118) 
1.041  
(0.972, 1.114) 
0.575 
Anxiety 
disorder 
3966 
1.053 
(0.960, 1.154) 
1.157 
(1.064, 1.258) 
1.109  
(1.038, 1.186) 
0.105 
Negative 
symptoms 
Depressive 
disorder 
2872 
1.171  
(1.055, 1.301) 
0.994  
(0.895, 1.105) 
1.080  
(0.998, 1.168) 
0.020 
Anxiety 
disorder 
2873 
1.169  
(1.053, 1.298) 
1.161  
(1.052, 1.282) 
1.165  
(1.078, 1.258) 
0.917 
Depressive 
disorder 
Anxiety 
disorder 
4106 
1.008  
(0.925, 1.098) 
1.135  
(1.045, 1.232) 
1.073  
(1.004, 1.148) 
0.020 
Note: OR, Odds Ratio; LCI, L95% CI; UCI, U95% CI (see eMethods for details of how ORs were derived) 
a Complete case data, bivariate model estimation 
b P value calculated from likelihood ratio tests comparing a model assuming psychopathology-specific effect 
versus a common effect model where exposure effect is constrained to be the same across phenotypes. A p-
value of 0.5 for example would provide little evidence that the association between polygenic score and 
Phenotype 1 was different to that for the association between polygenic score and Phenotype 2. A p-value of 
0.01 for example would provide strong evidence that there was a difference. 
 
